Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11231, Cairo, Egypt.
Department of Biochemistry, Faculty of Pharmacy, Heliopolis University, Cairo, 11785, Egypt.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr;397(4):1957-1969. doi: 10.1007/s00210-023-02759-0. Epub 2023 Oct 6.
Pheochromocytoma (PCC) is a neuroendocrine tumor that produces and secretes catecholamine from either the adrenal medulla or extra-adrenal locations. MicroRNAs (miRNAs, miR) can be used as biomarkers to detect cancer or the return of a previously treated disease. Blood-borne miRNAs might be envisioned as noninvasive markers of malignancy or prognosis, and new studies demonstrate that microRNAs are released in body fluids as well as tissues. MiRNAs have the potential to be therapeutic targets, which would greatly increase the restricted therapy options for adrenal tumors. This article aims to consolidate and synthesize the most recent studies on miRNAs in PCC, discussing their potential clinical utility as diagnostic and prognostic biomarkers while also addressing their limitations.
嗜铬细胞瘤（PCC）是一种神经内分泌肿瘤，它可以从肾上腺髓质或肾上腺外部位产生和分泌儿茶酚胺。microRNAs（miRNAs，miR）可用作生物标志物来检测癌症或以前治疗疾病的复发。血源性miRNAs 可以被视为恶性或预后的非侵入性标志物，新的研究表明，miRNAs 也会从体液和组织中释放出来。miRNAs 具有作为治疗靶点的潜力，这将极大地增加肾上腺肿瘤的有限治疗选择。本文旨在整合和综合 PCC 中 miRNAs 的最新研究，讨论其作为诊断和预后生物标志物的潜在临床应用，同时也解决其局限性。
